Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05650645 · ClinicalTrials.gov registry record · Phase 2
The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial
A Phase 2 study of Tinnitus, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT05650645: Completed Phase 2 study of Tinnitus, sponsored by University of Minnesota.
NCT05650645 is a Phase 2 study of Tinnitus that has completed, run by University of Minnesota. The registered enrollment target is 41 participants, below the 12,618-participant average among 24 other Tinnitus trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05650645, a Phase 2 study of Tinnitus, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Tinnitus is a persistent non-physiologic, non-psychiatric, ringing in the ear that affects up to 20% of the general US population. The purpose of this study is to assess the patient reported effectiveness of Xeomin (incobotulinumtoxinA) injections into the auricular muscles for relief of tinnitus with use of the Tinnitus Handicap Inventory questionnaire.
Primary Outcome
in the group assigned to placebo for the first stage
Conditions Studied
Interventions
- DRUG incobotulinum toxin A
- DRUG Placebo-Saline
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2025-12-29 |
| Phase | Phase 2 |
What the finished NCT05650645 record still lists
NCT05650645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 12,618-participant average among 24 other Tinnitus trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Tinnitus appearing as the primary indexed condition, and to 2 interventions - of which incobotulinum toxin A is the first listed.
NCT05650645 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05650645 about?
NCT05650645 is a clinical study titled "The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial". Tinnitus is a persistent non-physiologic, non-psychiatric, ringing in the ear that affects up to 20% of the general US population. The purpose of this study is to assess the patient reported effectiveness of Xeomin (incobotulinumtoxinA) injections into the auricular muscles for relief of tinnitus wi...
What is the current status of trial NCT05650645?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2023-01-01. Estimated completion is 2025-12-29.
What conditions does trial NCT05650645 study?
This clinical trial studies the following conditions: Tinnitus.
What interventions are being tested in trial NCT05650645?
The interventions under investigation include: incobotulinum toxin A (DRUG), Placebo-Saline (DRUG).
Who is sponsoring clinical trial NCT05650645?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05650645 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinnitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05650645's enrollment target sits among peer trials
41 18th of 24 higher than 7 of 24 other Tinnitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tinnitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zinc to Treat Tinnitus in the Elderly
COMPLETED · Phase 2
-
Evaluation of Treatment Methods for Clinically Significant Tinnitus
COMPLETED · Phase 2
-
Treatment for PTSD and Tinnitus
RECRUITING · NA
-
Investigating EEG as a Biomarker for Tinnitus Improvement After Bimodal Stimulation
RECRUITING · NA
-
Somatosensory Tinnitus RCT
RECRUITING · NA
-
An fMRI Investigation of the Effects of IV Lidocaine on Tinnitus
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI